Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
- Written by ACN Newswire - Press Releases

Tazemetostat is a first-in-class, oral EZH2 inhibitor discovered by Epizyme,...

Tazemetostat is a first-in-class, oral EZH2 inhibitor discovered by Epizyme,...

A new generation of young Australian small business owners is redefining success, driven by a desire to create a lasting legacy through the positi...

In a world where many small businesses are still trying to work out how to actually use AI (not just talk about it), Australian fintech LoanOption...

The world of mobility is changing fast, and car ownership is no longer the default. Across Australia, professionals and businesses alike are seeki...

“You shouldn’t need a large account balance to experience real-time investing. Technology should make that kind of access universal.” For decades...

Thryv® (NASDAQ: THRY), Australia’s provider of the leading small business marketing and sales software platform, announced that Greg Nicolle, G...

pay.com.au, the end-to-end payments and rewards platform, today announced the launch of International Payments, Australia’s first foreign exchange...